Cronos Group Inc. CRON
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About CRON
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Cronos Group Inc. is a cannabinoid company focused on the research, production, marketing, and distribution of cannabis and hemp-derived products. The company operates within the global cannabis, consumer packaged goods, and biotechnology-oriented cannabinoid sectors. Cronos develops products for both adult-use recreational and medical cannabis markets, with operations spanning cultivation, manufacturing, branded consumer products, and cannabinoid research. Its primary revenue drivers include cannabis flower, pre-rolls, vapes, edibles, extracts, and cannabinoid ingredient sales under multiple consumer brands.
The company serves adult-use consumers, medical cannabis patients, and cannabinoid ingredient customers across several international markets. Cronos is positioned as a science-driven cannabis operator with a focus on product innovation, intellectual property development, and strategic partnerships. A major differentiator has been its long-standing strategic investment relationship with Altria Group, which acquired a significant equity stake in 2019 and provided capital for expansion and product development initiatives. Cronos traces its origins to Peace Naturals Project Inc., one of Canada’s early licensed medical cannabis producers, before rebranding as Cronos Group and expanding internationally following cannabis legalization developments in Canada and other jurisdictions.
Business Operations
Cronos generates revenue through branded cannabis product sales, cannabis cultivation and processing, and cannabinoid research and development activities. Its core operations include cultivation facilities, manufacturing assets, extraction capabilities, and branded product distribution. The company’s operating structure has historically included business units and subsidiaries such as Cronos GrowCo, Peace Naturals, and U.S.-focused hemp-derived CBD operations under Lord Jones. Cronos has also developed intellectual property and fermentation-based cannabinoid technologies through partnerships and internal R&D efforts.
The company operates in both domestic and international markets, with Canada remaining a principal source of revenue through adult-use cannabis sales. International operations have included activities in Israel, Germany, Australia, and other regulated cannabis markets through exports, partnerships, and distribution arrangements. Cronos has maintained strategic collaborations with biotechnology and cannabinoid research firms to advance rare cannabinoid production and product innovation. Revenue is primarily generated from branded cannabis products sold through provincial distributors, medical channels, and international markets where regulations permit cannabis imports.
Strategic Position & Investments
Cronos has emphasized a strategy centered on brand development, cannabinoid science, and disciplined capital allocation. The company has invested in next-generation cannabinoid production technologies, including biosynthesis and fermentation methods designed to efficiently produce rare cannabinoids at scale. Strategic initiatives have focused on expanding product categories, improving manufacturing efficiency, and developing differentiated consumer brands in competitive cannabis markets.
The company’s most significant strategic relationship remains its investment and partnership with Altria Group, which provided substantial funding and commercial expertise. Cronos has also pursued acquisitions and investments aimed at strengthening its intellectual property portfolio and consumer product capabilities, including the acquisition of Lord Jones, a hemp-derived CBD brand. The company has participated in emerging cannabinoid sectors involving minor cannabinoids and alternative production technologies, although the commercial scale and long-term profitability of some initiatives remain subject to evolving market and regulatory conditions. Public disclosures indicate continued prioritization of cash preservation and operational efficiency amid broader cannabis industry volatility.
Geographic Footprint
Cronos is headquartered in Toronto, Canada, and maintains operational and commercial activities across multiple international jurisdictions. The company’s primary commercial presence is in Canada, where it participates in the federally regulated adult-use cannabis market through provincial distribution systems. It has also maintained cultivation, manufacturing, research, and export-related activities connected to international cannabis markets.
Beyond North America, Cronos has established market exposure in regions including Europe, the Middle East, and Australia through export agreements, medical cannabis distribution, and strategic partnerships. Historically, Israel has represented an important international market due to medical cannabis demand and import opportunities. The company’s international strategy has generally focused on jurisdictions with federally regulated cannabis frameworks and pathways for medical cannabis commercialization.
Leadership & Governance
Cronos Group is governed by a board of directors and executive leadership team focused on consumer brand development, cannabinoid innovation, and regulatory compliance within the evolving global cannabis industry. Leadership has emphasized scientific research, disciplined investment practices, and long-term positioning in regulated cannabinoid markets. Governance practices and executive oversight are disclosed through public filings including SEC filings and annual reports.
Key executives have included:
- Mike Gorenstein – Chairman, President and Chief Executive Officer
- James Holm – Chief Financial Officer
- Rebecca Irvine – Chief Legal Officer and Corporate Secretary
- Steve Habif – Chief Transformation Officer
- John Hill – Chief Commercial Officer
Company leadership has publicly emphasized building scalable cannabinoid consumer brands, leveraging research and development capabilities, and maintaining financial flexibility amid changing cannabis market conditions. Some executive roles and organizational structures have changed over time; current leadership details should be confirmed through the company’s latest regulatory filings and investor materials.